EP1976851A2 - Pyrimidines substituees par un groupe phenoxy en tant qu'antagonistes des recepteurs d adenosine - Google Patents

Pyrimidines substituees par un groupe phenoxy en tant qu'antagonistes des recepteurs d adenosine

Info

Publication number
EP1976851A2
EP1976851A2 EP07718002A EP07718002A EP1976851A2 EP 1976851 A2 EP1976851 A2 EP 1976851A2 EP 07718002 A EP07718002 A EP 07718002A EP 07718002 A EP07718002 A EP 07718002A EP 1976851 A2 EP1976851 A2 EP 1976851A2
Authority
EP
European Patent Office
Prior art keywords
methyl
pyrimidin
furan
phenoxy
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07718002A
Other languages
German (de)
English (en)
Inventor
Deborah Slee
Xiaohu Zhang
Jaimie K. Rueter
Emily Lin
Maria Isabel Crespo Crespo
Julio Cesar Castro Palomino Laria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Laboratorios Almirall SA
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Almirall SA, Neurocrine Biosciences Inc filed Critical Laboratorios Almirall SA
Publication of EP1976851A2 publication Critical patent/EP1976851A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés répondant à la formule (I), comprenant des sels pharmaceutiquement acceptables, des esters, des solvates, des stéréoisomères et des promédicaments de ceux-ci, dans laquelle R1, R2, R3, R4, R5, X, m et n sont tels que définis dans le présent document. La présente invention concerne également des compositions pharmaceutiques contenant un composé répondant à la formule (I), ainsi que des procédés se rapportant à l’utilisation de ceux-ci.
EP07718002A 2006-01-17 2007-01-17 Pyrimidines substituees par un groupe phenoxy en tant qu'antagonistes des recepteurs d adenosine Withdrawn EP1976851A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75969206P 2006-01-17 2006-01-17
PCT/US2007/060632 WO2007084914A2 (fr) 2006-01-17 2007-01-17 Pyrimidines substituees par un groupe phenoxy en tant qu'antagonistes des recepteurs d’adenosine

Publications (1)

Publication Number Publication Date
EP1976851A2 true EP1976851A2 (fr) 2008-10-08

Family

ID=38169639

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07718002A Withdrawn EP1976851A2 (fr) 2006-01-17 2007-01-17 Pyrimidines substituees par un groupe phenoxy en tant qu'antagonistes des recepteurs d adenosine

Country Status (2)

Country Link
EP (1) EP1976851A2 (fr)
WO (1) WO2007084914A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008003811A1 (es) * 2007-12-21 2009-05-22 Palau Pharma Sa Compuestos derivados de 4-aminopirimidina-2,6-disustituidos, antagonistas del receptor de histamina h4; proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad alergica, inmunologica o inflamatoria, o dolor.
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
PT2797416T (pt) 2011-12-28 2017-10-23 Global Blood Therapeutics Inc Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
MY180206A (en) 2013-03-15 2020-11-25 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015031285A1 (fr) * 2013-08-27 2015-03-05 Global Blood Therapeutics, Inc. Sels d'ansolvats 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde cristallins
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015116061A1 (fr) * 2014-01-29 2015-08-06 Global Blood Therapeutics, Inc. Produits d'addition 1:1 d'hémoglobine s
US9248199B2 (en) 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
DK3102208T3 (da) 2014-02-07 2021-03-08 Global Blood Therapeutics Inc Krystallinsk polymorf af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2020072377A1 (fr) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulateurs de l'hémoglobine pour le traitement de la drépanocytose

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83101C2 (en) * 2003-12-15 2008-06-10 Алмирал Аг 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
ATE502936T1 (de) * 2005-04-11 2011-04-15 Almirall Sa 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007084914A2 *

Also Published As

Publication number Publication date
WO2007084914A3 (fr) 2007-10-04
WO2007084914A2 (fr) 2007-07-26

Similar Documents

Publication Publication Date Title
WO2007084914A2 (fr) Pyrimidines substituees par un groupe phenoxy en tant qu'antagonistes des recepteurs d’adenosine
EP2552909B1 (fr) Dérivés de 4-aminopyrimidine et leur utilisation en tant qu'antagonistes des récepteurs de l'adénosine a2a
JP6954567B2 (ja) ２−置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途
US20100234341A1 (en) Substituted pyrimidines as adenosine receptor antagonists
US20080058356A1 (en) 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists
JP2010511727A5 (fr)
JP2007514003A6 (ja) アデノシン受容体アンタゴニストとしての２，６−ビスヘテロアリール−４−アミノピリミジン
CA2631438A1 (fr) Composes organiques
US20100249084A1 (en) Substituted pyrimidines as adenosine receptor antagonists
JP2023036991A (ja) Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法
US7329678B2 (en) Chemical compounds
WO2007116106A1 (fr) Nouveaux composés utilisés comme antagonistes des récepteurs a1 de l'adénosine
WO2017088755A1 (fr) Composé aminopyrimidine hétérocyclique présentant une activité antagoniste du récepteur de l'adénosine
US20060205740A1 (en) Chemical compounds
WO2021099838A1 (fr) Composés antagonistes du récepteur de l'adénosine
US20240083896A1 (en) Nitrogen Containing 2,3-Dihydroquinazolinone Compounds as Nav1.8 Inhibitors
US9498478B2 (en) Spiro aminic compounds with NK1 antagonist activity
Colotta et al. Synthesis of 4-amino-6-(hetero) arylalkylamino-1, 2, 4-triazolo [4, 3-a] quinoxalin-1-one derivatives as potent A2A adenosine receptor antagonists
US20120157482A1 (en) Compounds and methods
US7368462B1 (en) Melanin concentrating hormone antagonists
WO2019141096A1 (fr) Composé d'urée substitué, son procédé de préparation et son utilisation
ZA200604823B (en) 2,6 Bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
TWI750645B (zh) 四氫哌喃基胺基-吡咯並嘧啶酮和使用彼之方法
US20230406838A1 (en) Mutant selective egfr inhibitors and methods of use thereof
CA2716202A1 (fr) Derives de pyrrolo[2,3-d]pyrimidin-2-ylamine comme inhibiteurs de pkc-theta

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080730

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20090401

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALMIRALL, S.A.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALMIRALL, S.A.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110731